Table 2.
Paired comparison of clinical parameters between baseline and week 2 in different outcomes and treatment groups
| |
Overall |
|
Survival |
|
Mortality |
|
Telbivudine |
|
Entecavir |
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Patient no |
21 |
|
17 |
|
4 |
|
9 |
|
12 |
|
|||||
| Time point | Baseline | Week 2 | p | Baseline | Week 2a | p | Baseline | Week 2a | P | Baseline | Week 2b | p | Baseline | Week 2b | p |
| ALT |
1270 (146–2480) |
167 (41–485) |
<0.001 |
1270 (211–2480) |
184 (41–485) |
<0.001 |
1197 (146–2247) |
112.5 (66–190) |
0.068 |
1523 (211–2480) |
184 (80–435) |
0.011 |
870 (146–2247) |
133.5 (41–485) |
0.002 |
| Bilirubin T |
9.2 (2.1–33.1) |
6.8 (1.8–43.2) |
0.728 |
7.7 (2.1–16.8) |
4.8 (1.8–21.3) |
0.309 |
20.6 (11.9–33.1) |
29.1 (17.8–43.2) |
0.068 |
8.6 (2.1–20.4) |
8.0 (1.9–25.3) |
0.515 |
10.25 (2.2–33.1) |
5.15 (1.8–43.2) |
1.000 |
| Creatinine |
0.68 (0.39–1.46) |
0.94 (0.37–3.79) |
0.002 |
0.71 (0.47–1.34) |
1.0 (0.37–1.81) |
0.019 |
0.48 (0.39–1.46) |
0.92 (0.72–3.79) |
0.068 |
0.71 (0.47–1.05) |
0.90 (0.59–1.49) |
0.051 |
0.63 (0.39–1.46) |
1.03 (0.37–3.79) |
0.021 |
| eGFR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MDRD |
116 (53–254) |
89 (18–241) |
0.005 |
116 (53–183) |
77 (37–241) |
0.042 |
194.5 (54–254) |
90.5 (18–129) |
0.068 |
116 (73–201) |
89 (37–147) |
0.044 |
127 (53–254) |
79 (18–241) |
0.050 |
| CKD-EPI |
111.1 (52.9–156.7) |
98.3 (18.9–134.5) |
0.003 |
110.1 (52.9–131.1) |
82.9 (36.8–134.5) |
0.028 |
138.2 (59.8–156.7) |
101.8 (18.9–126.4) |
0.068 |
112 (77.8–148) |
98.3 (40.9–126.4) |
0.066 |
110.6 (5.29–56.7) |
86.9 (18.9–134.5) |
0.028 |
| INR |
1.6 (1.3–3.5) |
1.4 (1.0–4.2) |
0.066 |
1.5 (1.3–2.3) |
1.3 (1.0–2.8) |
0.062 |
3.3 (2.6–3.5) |
2.75 (2.2–4.2) |
0.577 |
1.5 (1.3–3.1) |
1.7 (1.1–2.8) |
0.440 |
1.6 (1.4–3.5) |
1.35 (1.0–4.2) |
0.058 |
| AFP |
65.7 (4.1–650.7) |
305.5 (6.2–2802) |
0.013 |
49.4 (4.1–477.2) |
459.6 (35.4–2802) |
0.005 |
109.5 (27.9–650.7) |
36.3 (6.2–66.3) |
0.180 |
27.9 (4.2–238.3) |
191.9 (66.3–1462.5) |
0.046 |
162.1 (4.1–650.7) |
459.6 (6.2–2802) |
0.139 |
| HBV DNA (log10 cps/ml) |
8.04 (4.3–9.68) |
4.19 (3.07–5.89) |
<0.001 |
8.16 (5.22–5.06) |
4.2 (3.07–5.89) |
0.001 |
5.06 (4.3–8.2) |
3.64 (3.31–3.96) |
0.180 |
8.04 (4.97–9.47) |
3.96 (3.07–5.10) |
0.018 |
8.04 (4.30–9.68) |
4.20 (3.13–5.89) |
0.005 |
| MELD score | 20 (13–37) | 19 (11–49) | 0.283 | 19 (13–28) | 17 (11–32) | 0.166 | 31.5 (26–.7) | 30 (26–49) | 0.655 | 19 (14–31) | 20 (11–32) | 0.674 | 20 (13–37) | 18 (11–49) | 0.469 |
Data shown as median (range); eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease (mL/min/1.73m2), CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (mL/min/1.73m2), INR international normalized ratio, AFP alpha-fetoprotein, MELD model for end-stage liver disease.
a: comparison of week 2 data between survival and mortality, p values in order were 0.324, 0.003, 0.720, 0.788, 1.000, 0.004, 0.039, 0.160, 0.006.
b: comparison of week 2 data between Telbivudine and Entecavir, p values in order were 0.394, 0.776, 0.776, 0.803, 0.670, 0.642, 1.000, 0.242, 0.915.